Neogenomics Inc
F:NG9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Neogenomics Inc (NG9) under the Base Case is 10.31 EUR per share.
Compared with the current market price of 14.745 EUR, the stock appears
Overvalued by 30% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Neogenomics Does
Neogenomics is a specialty laboratory company focused on cancer testing. It runs tests on tissue, blood, and bone marrow to help doctors diagnose cancer, classify tumors, and choose treatments. Its main customers are oncologists, hospitals, pathology groups, and other medical providers that need detailed cancer lab results.
- Headquarters
- United States of America US
- Employees
- 2 500
- IPO date
- Dec 10, 2012
Neogenomics has no economic moat
Neogenomics Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Neogenomics Inc
Earnings Waterfall
Neogenomics Inc
What is the Intrinsic Value of one NG9 stock?
The intrinsic value for Neogenomics Inc (NG9) under the Base Case is 10.31 EUR.
Is NG9 stock undervalued or overvalued?
Compared with the current market price of 14.745 EUR, the stock appears Overvalued by 30% .
